Shares of GlaxoSmithKline plc (LON:GSK) have been assigned a consensus recommendation of “Hold” from the eighteen analysts that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is GBX 1,597.92 ($20.88).

A number of analysts have weighed in on the company. Shore Capital downgraded GlaxoSmithKline to a “hold” rating in a report on Friday, January 18th. HSBC set a GBX 1,820 ($23.78) price target on GlaxoSmithKline and gave the stock a “buy” rating in a report on Friday, January 25th. Liberum Capital reiterated a “hold” rating and set a GBX 1,510 ($19.73) price target on shares of GlaxoSmithKline in a report on Monday, January 21st. Deutsche Bank set a GBX 1,520 ($19.86) price target on GlaxoSmithKline and gave the stock a “neutral” rating in a report on Thursday, December 20th. Finally, Barclays reiterated an “equal weight” rating on shares of GlaxoSmithKline in a report on Tuesday, January 15th.

LON GSK traded up GBX 3.40 ($0.04) on Friday, reaching GBX 1,565 ($20.45). The company had a trading volume of 8,956,494 shares, compared to its average volume of 9,120,000. The company has a market capitalization of $76.83 billion and a price-to-earnings ratio of 21.47. GlaxoSmithKline has a fifty-two week low of GBX 1,281.60 ($16.75) and a fifty-two week high of GBX 1,648.80 ($21.54). The company has a quick ratio of 0.47, a current ratio of 0.75 and a debt-to-equity ratio of 709.80.

The company also recently announced a dividend, which will be paid on Thursday, April 11th. Stockholders of record on Thursday, February 21st will be paid a GBX 23 ($0.30) dividend. The ex-dividend date is Thursday, February 21st. This is an increase from GlaxoSmithKline’s previous dividend of $19.00. This represents a dividend yield of 1.49%. GlaxoSmithKline’s dividend payout ratio (DPR) is currently 1.26%.

In other news, insider Jesse Goodman bought 845 shares of GlaxoSmithKline stock in a transaction dated Wednesday, February 6th. The stock was bought at an average cost of GBX 1,964 ($25.66) per share, for a total transaction of £16,595.80 ($21,685.35). Also, insider Victoria Whyte bought 3,020 shares of GlaxoSmithKline stock in a transaction dated Wednesday, February 13th. The stock was purchased at an average price of GBX 1,547 ($20.21) per share, with a total value of £46,719.40 ($61,047.17). Over the last 90 days, insiders bought 3,881 shares of company stock valued at $6,356,144.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Article: What are no-load funds?

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.